Evidence map›Paper›PMID 35024944›Full record

ReviewWorld journal of urology2022

Management of patients with a persistently elevated PSA after radical prostatectomy: a narrative review.

I Latorzeff, G Ploussard, M D Faye, U Schick, N Benziane-Ouaritini, T M Niazi, F Saad, P Sargos

Abstract readReview
PubMed Publisher
In one paragraph

Review in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

I LatorzeffDepartment of Radiation Oncology, Bât Atrium, Clinique Pasteur, 1 rue de la petite vitesse, 31300, Toulouse, France. i.latorzeff@clinique-pasteur.com.ORCID http://orcid.org/0000-0001-5935-5218
G PloussardDepartment of Urology, Clinique La Croix du Sud, Quint Fonsegrives, France.
M D FayeDepartment of Radiation Oncology, McGill University, Montreal, QC, Canada.
U SchickDepartment of Radiation Oncology, CHU de Brest, Brest, France.
N Benziane-OuaritiniDepartment of Radiation Oncology, Institut Bergonié, Bordeaux, France.
T M NiaziDepartment of Radiation Oncology, McGill University, Montreal, QC, Canada.
F SaadCRCHUM, Montreal, QC, Canada.
P SargosDepartment of Radiation Oncology, Institut Bergonié, Bordeaux, France.
Institut Bergonié · FRMcGill University · CACentre Hospitalier Régional Universitaire de Brest · FRClinique Pasteur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe management of the postoperative biological relapse of prostate cancer is most often based on salvage radiotherapy (SRT) with or without the addition of a variable duration of hormone therapy (HT). The indications for SRT +/- HT are established in the setting of a rising PSA level after a period where an undetectable PSA was achieved. However, in case of detectable PSA immediately after radical prostatectomy, the treatment options and prognosis are still unclear. MATERIALS AND

methodsWe conducted a narrative review based on an analysis of the literature focusing on articles targeting the population of patients with postoperative persistently detectable PSA level. Case reports, original articles, clinical trials, and published reviews were studied for this purpose.

conclusionThis article will describe current management of patients with detectable PSA immediately after radical prostatectomy, notably the contribution of modern imaging and new treatment options involving the combination of RT and HT.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsHumansMaleNeoplasm Recurrence, LocalProstateProstatectomySalvage TherapyProstate-Specific AntigenClinical trialsDetectable persistent PSApN0 patientsProstate cancerSalvage radiation therapySalvage radiotherapy

Identifiers

PMID35024944
OpenAlexW4205507214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.